

June 16, 2023

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Atsushi Udoh, Representative Director, CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer and General Manager, Corporate Communications and Investor Relations Division (TEL: 81-3-6838-2803)

Notice Regarding Launch of
1 Ingredient / 3 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Yasuyuki Kumada), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 1 ingredient / 3 products of generic drugs today on June 16, 2023 as below.

New products list

Class	Product Name	Original Brand Name
Persistent AT1 receptor blocker	AZILSARTAN TABLETS 10mg/20mg/40mg “TOWA”	AZILVA®Tablets 10mg/20mg/40mg